# Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

> **NCT01598025** · NA · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Acute Leukemia
- Chronic Leukemia
- Myelodysplastic Syndrome
- Non-Hodgkins Lymphoma

## Interventions

- **RADIATION:** total-body irradiation (TBI)
- **DRUG:** thiotepa
- **DRUG:** fludarabine phosphate
- **DRUG:** melphalan
- **BIOLOGICAL:** anti-thymocyte globulin
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **BIOLOGICAL:** peripheral blood stem cell transplantation
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01598025
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-02
- **Primary completion:** 2017-10-16
- **Final completion:** 2017-10-16
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Closed due to poor accrual
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01598025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01598025, "Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01598025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*